Skip to main content

Advertisement

Table 3 Subjects allocation per trial arm and subgroup and baseline characteristics

From: A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial

  Gender Age BMI (kg/m2) GI symp. DTS a
Cohort Treatment n Males (n) Females (n) Range Median Range Median Mean (± SEM)
Total cohort (n = 80) EpiCor 40 7 33 20–69 50 18–33 24 7.20 ± 0.56
Placebo 40 6 34 21–65 45 18–35 24 6.56 ± 0.46
Severe (n = 55) EpiCor 28 5 23 24–66 48 18–33 24 8.68 ± 0.60
Placebo 27 3 24 21–65 44 18–33 24 8.08 ± 0.42
Moderate (n = 25) EpiCor 12 2 10 20–69 57 19–33 23 3.74 ± 0.31
Placebo 13 3 10 23–63 52 20–35 22 3.41 ± 0.32
  1. Legend: BMI, body mass index; GI, gastrointestinal
  2. aAverage of daily total scores (DTS) obtained after 2-week run-in on GI symptoms. This score was used to allocate subjects within the two subgroups (severe: GI symptoms ≥ 5 and moderate: GI symptoms <5)